Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05680818 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
A Phase 3 study of Autosomal Dominant Hypocalcemia (ADH), sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- Active
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
- 20
- Study locations
NCT05680818 is a Phase 3 study of Autosomal Dominant Hypocalcemia (ADH) that is active but no longer recruiting, run by Calcilytix Therapeutics, Inc., a BridgeBio company. The registered enrollment target is 67 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05680818, a Phase 3 study of Autosomal Dominant Hypocalcemia (ADH), is active but no longer recruiting, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Conditions Studied
Interventions
- DRUG Encaleret
- DIETARY_SUPPLEMENT Standard of Care
Study Locations (20)
Other
- Vseobecna fakultni nemocnice v Praze - New Town
- Aarhus University Hospital - Aarhus
- Hôpital Edouard Herriot - HCL - Lyon
- IRCCS Ospedale San Raffaele - Milan
- University Hospital of Pisa - Pisa
California
- UCSF Benioff Children's Hospital, Oakland - Oakland
Colorado
- Children's Hospital Colorado - Aurora
Indiana
- Indiana University Health University Hospital - Indianapolis
Maryland
- NIH - Bethesda
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester - Rochester
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2023-01-06 |
| Est. Completion | 2029-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05680818
The ClinicalTrials.gov registry entry for NCT05680818 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Hypocalcemia (ADH) appearing as the primary indexed condition, and to 2 interventions - of which Encaleret is the first listed.
NCT05680818 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05680818 about?
NCT05680818 is a clinical study titled "Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1". The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
What is the current status of trial NCT05680818?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2023-01-06. Estimated completion is 2029-08.
What conditions does trial NCT05680818 study?
This clinical trial studies the following conditions: Autosomal Dominant Hypocalcemia (ADH).
What interventions are being tested in trial NCT05680818?
The interventions under investigation include: Encaleret (DRUG), Standard of Care (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05680818?
This trial is sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05680818 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.